宝莫股份(002476) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 134,389,767.07, representing a 36.57% increase compared to CNY 98,407,036.72 in the same period last year[5] - Net profit attributable to shareholders was CNY 6,526,072.15, a significant increase of 266.31% from a loss of CNY 3,923,995.10 in the previous year[5] - Basic and diluted earnings per share improved to CNY 0.0107, compared to a loss of CNY 0.0064 in the previous year, marking a 267.19% increase[5] - Total operating revenue for Q1 2024 reached CNY 134,389,767.07, an increase of 36.5% compared to CNY 98,407,036.72 in Q1 2023[25] - Net profit for Q1 2024 was CNY 6,526,072.15, a significant recovery from a net loss of CNY 3,923,995.10 in Q1 2023[26] - Earnings per share for Q1 2024 were CNY 0.0107, compared to a loss per share of CNY 0.0064 in the previous year[27] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 61.73% to CNY 11,804,765.86, down from CNY 30,844,660.76 in the same period last year[12] - The net cash flow from operating activities for the current period is ¥11,804,765.86, a decrease of 61.7% compared to ¥30,844,660.76 in the previous period[30] - Total cash inflow from operating activities is ¥123,300,275.03, down 40% from ¥205,839,435.45 in the previous period[30] - Cash outflow from operating activities is ¥111,495,509.17, a decrease of 36.2% compared to ¥174,994,774.69 in the previous period[30] - The net cash flow from investment activities is -¥2,116,764.65, slightly improved from -¥2,187,566.80 in the previous period[30] - Cash inflow from financing activities is ¥0, compared to ¥14,950,000.00 in the previous period[30] - Cash outflow from financing activities is ¥5,694,340.00, down 46.5% from ¥10,619,965.32 in the previous period[30] - The net increase in cash and cash equivalents is ¥3,993,661.21, significantly lower than ¥32,987,128.64 in the previous period[30] - The ending balance of cash and cash equivalents is ¥267,824,578.30, compared to ¥273,576,153.84 in the previous period[30] - As of March 31, 2024, the company's cash and cash equivalents amounted to RMB 270,096,109.98, an increase from RMB 267,083,996.53 at the beginning of the period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 965,517,028.39, a slight increase of 0.14% from CNY 964,151,009.85 at the end of the previous year[5] - Total liabilities decreased to CNY 82,505,873.14 in Q1 2024 from CNY 87,093,868.75 in Q1 2023, reflecting a reduction of 5.9%[23] - The company reported a decrease in short-term borrowings to CNY 16,930,000.00 from CNY 21,880,000.00, a reduction of 22.5% year-over-year[23] - The company has reported a significant decrease in notes receivable from RMB 12,438,054.91 to RMB 1,691,950.59, suggesting a tightening of credit terms or collection efforts[21] Operational Costs - The company reported a 32.60% increase in operating costs compared to the same period last year[11] - Total operating costs for Q1 2024 were CNY 127,208,640.83, up 24.2% from CNY 102,451,591.75 in the same period last year[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,919[14] Strategic Initiatives - The company has initiated a buyback request for its shares in Daying Mining due to project delays and complexities, indicating a strategic shift to mitigate investment risks[18] - A control transfer agreement was signed on October 31, 2023, for 15.8% of the company's shares, with the actual control changing to Luo Xiaolin and Han Ming couple as of January 5, 2024[19] - The company has completed the registration of the change in control, which may impact future strategic directions and governance[19] - The company plans to adjust its performance commitment scheme and provide financial support to its wholly-owned subsidiaries, reflecting a focus on internal growth and stability[17] - The company is actively pursuing new acquisition opportunities and has made adjustments to its financial strategies to enhance operational efficiency[18] Legal Matters - The company is involved in a legal dispute regarding a RMB 13 million equity transfer agreement with Xian Dao Pharmaceutical, with ongoing court proceedings and a ruling received on August 23, 2023[16] - The company has disclosed ongoing litigation and enforcement actions against Xian Dao Pharmaceutical, highlighting potential financial implications and risks associated with the equity transfer[16] Research and Development - Research and development expenses for Q1 2024 were CNY 4,500,835.98, slightly down from CNY 4,849,612.39 in Q1 2023[26] Accounting and Auditing - The company has not undergone an audit for the first quarter report[32] - The company has adopted new accounting standards starting from 2024[31]